Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Thor Halfdanarson has the following disclosures: consulting/advisory board for Curium, Terumo, Advanced Accelerator Applications, Novartis, Crinetics, and ITM. He has received research support from Advanced Accelerator Applications, Novartis, Basilea, Agios, Turnstone Biologics, and Thermo Fisher Scientific.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alva-Ruiz, R., Yohanathan, L., Yonkus, J.A. et al. ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol 29, 1594–1595 (2022). https://doi.org/10.1245/s10434-021-11076-w
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-11076-w